Pfizer Inc/stats, details

From SourceWatch
Jump to: navigation, search

Detailed Information

Business Structure

Lines of business

Human Healthcare (prescription drug products)

Animal Healthcare

Units/subsidiaries [1]

  • Embrex
  • Warner-Lambert
  • Parke-Davis
  • Animal Health Group
  • Pfizer Austria
  • Pfizer Canada
  • Pfizer Denmark
  • Pfizer Europe
  • Pfizer Global Research and Development
  • Pfizer Ireland
  • Pfizer Italy
  • Pfizer Japan
  • Pfizer Malaysia - Singapore
  • Pfizer Pharmaceuticals Group
  • Pfizer Spain
  • Pfizer Sweden
  • Pfizer Taiwan
  • Pfizer Turkey

Major Acquisitions

Warner-Lambert, February 2000

Pharmacia Corporation, April 2003

Esperion Therapeutics, February 2004

Vicuron Pharmaceutical, September 2005

Major Products By Patent Expiration Date

Zithromaxin(2005)
Zoloft(2006)
Norvasc (2007)
Zyrtec (2007)
Camptosar (2008)
Aricept (2010)
Lipitor (2010)
Viagra (2012)
Celebrex (2014)
Lyrica (2018)
Sutent (2021)

Wholesalers

2006: Percent of Total Revenue

  1. McKesson Inc 20%
  2. Cardinal Health Inc 13%
  3. AmerisourcesBergen Corp 11%

Competitors

Merck
Sanofi-Aventis
GlaxoSmithKline
Bristol-Myers Squibb

Creditors

Geographic scope

Countries of operation

Research and Development:

  • USA
  • China
  • England
  • France
  • Japan

Veterinary Medicine Research:

  • Australia

Global Manufacturing:

  • USA
  • Brazil
  • Belgium
  • Germany
  • Ireland
  • Italy
  • Mexico
  • Puerto Rico
  • Singapore
  • Sweden
  • United Kingdom

Breakdown of revenues[2]

2006: By Division

  • 93.2% Pharmaceutical Division
  • 4.8% Animal Health

By Geography

  • US Sales: 53.4% ($25.8 billion)
  • International Sales: 46.6% ($22.5 billion)
    • Japan: 6.7%(of total revenue)

By Major Product:

  1. Lipitor $12.9 billion
  2. Norvasc $4.87 billion
  3. Zoloft $2.1 billion
  4. Celebrex $2.04 billiion

2005:

  • 93.4% Pharmaceutical Division ($45 billion)
  • 4.6% Animal Health

Breakdown of profits

Breakdown of assets

Board members & affiliations[3]

Jeffrey B. Kindler, Chairman of the Board
Alan G Levin, Chief Financial Officer
Loretta Cangialosi, Chief Accounting Officer
Dennis Ausiello
Michael S. Brown
M. Anthoy Burns
Robert N. Burt
W. Don Cornwell
William H. Gray III

  • Former Congressman, Pennsylvania 2nd (1979-1991)
  • Director of Dell
  • Director of Prudecntial
  • Director of JP Morgan Chase

Constance J. Horner

  • Former Civil Rights Commissioner

William R. Howell

  • Former CEO, JC Penney (1983-1997)

Stanley O. Ikenberry

  • Director TIAA-CREF
  • Former President, American Council on Education (1996-2001)
  • Former President, University of Illinois (1979-1995)

George A. Lorch

  • CEO of Armstrong

Henry A. McKinnell, former CEO, Pfizer (2001-2006)

  • Chairman of PhRMA
  • Director of Stanford Graduate School of Business Advisory Council
  • Member Board of Trustees of NYC Public Library

Dana G. Mead

  • Member of the Executive Compensation Committee
  • retired CEO of Tenneco, Inc.
  • Chairman, MIT Corporation

Ruth J. Simmons

  • President, Brown University
  • Former President of Smith College
  • Director of Metropolitan Life
  • Director of Goldman Sachs Group
  • Director of Texas Instruments

Wiliam C. Steere, Jr., former CEO of Pfizer (1991-2001)

  • Director of Connecticut Mutal Life Insurance
  • Director of Texaco

Executive/director compensation

2006:

  1. Henry A. McKinnell: $12,968,829[4]

Date & venue of next AGM

Labor

98,000 worldwide

  • 38,000 sales representatives
  • 12,000 medical researchers[5]
  • Plan to eliminate 10,000 employees by end of 2008[6]
    • Includes a 20% reduction in European sales force
    • Closing of manufacturing plants in Brooklyn, NY and Omaha, NB.
    • Close research site in Michigan, Japan, and France

Domestic

Global

Basic Information

HQ Contact information

235 E. 42nd St.
New York, NY 10017
Phone: 212-573-2323
Fax: 212-573-7851
Web: http://www.pfizer.com

Country of incorporation

United States (Delaware)

Ownership status

Public

Primary industry sector

  • Pharmaceuticals
  • Animal Health

2007 Primary Industry Ranking

Fortune 500 Rank: 39 (2006, 31) [7]

Fortune Pharmaceutical Industry Rank: 2

Forbes 2000 Profit Rank: 7[8]

Financial Times Global 500: 17[9]

Number of employees worldwide

98,000

Chief executive officer

Jeffrey B. Kindler, 51

Financial information

Ticker symbol

PFE

Main exchanges

NYSE

Investor website

http://www.pfizer.com/investors

List of largest shareholders[10]

  • Barclays Global Investors, 5.13%
  • AXA, 3.21%
  • State Street Corporation, 3.14%
  • Vanguard Group, 2.94%
  • Capital Research and Management, 2.14%

Total revenue

2006 Net Sales: $48,370,000,000

Net income

2006 Net Income: $19,337,000,000

Books on company

  • Kanter, RM (ed). “Innovation: Breakthrough Thinking at 3M, DuPont, GE, Pfizer and Rubbermaid”, 1997.
  • McKinnell, Hank. “A Call to Action”, 2005.
  • Mines, S. “Pfizer: An Informal History”, 1978.
  • Pratt, Edmund T. “Pfizer: Bringing Science to Life”, 1985.
  • Reidy, Jamie. “Hard Sell: The Evolution of a Viagra Salesman”, 2005.
  • Rodengen, Jeffrey. “The Legend of Pfizer”, 1999.

Sources

  1. http://www.mind-advertising.com/us/pfizer_us.htm
  2. http://pfizer.com/investors/sec_filings.jsp
  3. http://www.nndb.com/company/608/000053449
  4. http://www.aflcio.org/corporatewatch/paywatch/ceou/database.cfm?tkr=PFE&pg=1
  5. http://www.oneworldtrust.org/?display=Pfizer
  6. http://www.iht.com/articles/2007/01/22/business/pfizer.php
  7. http://money.cnn.com/magazines/fortune/fortune500/2007/snapshots/1042.html
  8. http://www.forbes.com/lists/2007/18/biz_07forbes2000_The-Global-2000_Prof.html
  9. http://www.ft.com/reports/ft5002007
  10. http://finance.yahoo.com/q/mh?s=PFE

External resources

Google Newsfeed on Pfizer
Pfizer OSHA Report
AFL-CIO Executive Paywatch
Oxfam Report on Pfizer
http://en.wikipedia.org/wiki/Pfizer

External articles